- Home
- ERAS vs CDNL Comparison
ERAS vs CDNL Comparison
Compare ERAS & CDNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$9.53
Company Overview
Basic Information| Metric | ERAS | CDNL |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ERAS | CDNL |
|---|---|---|
| Price | $9.53 | $26.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $5.33 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 7.9M | 273.1K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1915.40 |
| Revenue | N/A | ★ $395,162,963.00 |
| Revenue This Year | N/A | $39.82 |
| Revenue Next Year | N/A | $18.41 |
| P/E Ratio | ★ N/A | $0.01 |
| Revenue Growth | N/A | ★ 59.39 |
| 52 Week Low | $1.01 | $21.98 |
| 52 Week High | $9.87 | $29.75 |
Technical Indicators
Market Signals| Indicator | ERAS | CDNL |
|---|---|---|
| Relative Strength Index (RSI) | 88.98 | N/A |
| Support Level | $3.36 | N/A |
| Resistance Level | $6.49 | N/A |
| Average True Range (ATR) | 1.01 | 0.00 |
| MACD | 0.57 | 0.00 |
| Stochastic Oscillator | 92.85 | 0.00 |
Price Performance
Historical Comparison ERAS
CDNL
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.